Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
RESEARCH TOOLSreports
Holding VTGN?
Track your performance easily
VTGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $5.74
Previous CloseN/A
Volume188.19K
Average Volume (3M)337.04K
Market Cap
$81.30M
Enterprise Value-$3.58M
Total Cash (Recent Filing)$2.92M
Total Debt (Recent Filing)$11.90K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Feb 18, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding27,843,466
10 Day Avg. Volume246,441
30 Day Avg. Volume337,041
Standard Deviation0.44
R-Squared0.00862
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)92.84
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.04
Enterprise Value/Revenue-3.94
Enterprise Value/Gross Profit-3.37
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$12.00Price Target Upside310.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
VistaGen Therapeutics News
PremiumCompany Announcements
VistaGen Therapeutics Advances Neurocircuitry Treatments
PremiumCompany Announcements
Vistagen Therapeutics Reports Increased R&D Expenses
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VTGN FAQ
What was VistaGen Therapeutics’s price range in the past 12 months?
VistaGen Therapeutics lowest stock price was $2.22 and its highest was $5.74 in the past 12 months.
What is VistaGen Therapeutics’s market cap?
VistaGen Therapeutics’s market cap is $81.30M.
When is VistaGen Therapeutics’s upcoming earnings report date?
VistaGen Therapeutics’s upcoming earnings report date is Feb 18, 2025 which is in 28 days.
How were VistaGen Therapeutics’s earnings last quarter?
VistaGen Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.029.
Is VistaGen Therapeutics overvalued?
According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued.
Does VistaGen Therapeutics pay dividends?
VistaGen Therapeutics does not currently pay dividends.
What is VistaGen Therapeutics’s EPS estimate?
VistaGen Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does VistaGen Therapeutics have?
VistaGen Therapeutics has 27,843,466 shares outstanding.
What happened to VistaGen Therapeutics’s price movement after its last earnings report?
VistaGen Therapeutics reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 0.641%.
Which hedge fund is a major shareholder of VistaGen Therapeutics?
Currently, no hedge funds are holding shares in VTGN
---
VistaGen Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (310.96% Upside)
$12.00 (310.96% Upside)
Blogger Sentiment
Bullish
VTGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.04%
12-Months-Change
Fundamentals
Return on Equity
-61.52%
Trailing 12-Months
Asset Growth
142.91%
Trailing 12-Months
Company Description
VistaGen Therapeutics
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
---
VTGN Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant progress in Vistagen's novel neuroscience pipeline, with multiple successful trials and ongoing developments. Despite increased expenses and potential delays in protocol submissions, the company's strong financial position and strategic advancements indicate positive momentum.Read More>---
VTGN Stock 12 Month Forecast
Average Price Target
$12.00
▲(310.96% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Cyclerion Therapeutics
―
Geron
―
Kazia Therapeutics
―
Eton Pharmaceuticals
―
Fennec Pharmaceuticals
―
Best Analysts Covering VTGN
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-26.47%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -26.47% per trade.
---